@article{JTD14886,
author = {Alessio Mattesini and Simone Bartolini and Carlotta Sorini Dini and Serafina Valente and Guido Parodi and Miroslava Stolcova and Francesco Meucci and Carlo Di Mario},
title = {The DESolve novolimus bioresorbable Scaffold: from bench to bedside},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {Suppl 9},
year = {2017},
keywords = {},
abstract = {The DESolve (Elixir Medical Corporation, Sunnyvale, California, USA) is a poly-L lactide-based polymer scaffold coated with the antiproliferative and anti-inflammatory drug novolimus. The scaffold biodegrades within one year with a complete resorption in two years and in vitro bench test have shown the ability to supply the necessary radial strength to support the vessel for the critical 3- to 4-month period after implant. The DESolve showed the unique self-correction property, which may reduce the incidence of minor malapposition after deployment. Overexpansion with DESolve is safe since a high capability resistance to fracture has been demonstrated with this scaffold. The aim of this review is to provide a comprehensive overview of the available preclinical and clinical data regarding the DESolve.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/14886}
}